Clinical Trial Search

Primary: Change From Baseline in WJ-III Basic Reading Normative Update (Woodcock Johnson Psychoeducational Battery - 3rd Edition; WJ-III NU) Standard Score at 15 Hours — 13.50…

Primary: the AFS Score at Second-look Hysteroscopy — 1.6; 1.9 units on a scale — p=>0.05

Primary: GSR Trial 1 — .62; .55; .55; .67 units on a scale

Primary: Percentage of Participants With Pathologic Complete Response (PCR) — 28.6; 40.7 percentage of participants

Primary: Change of Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Month 12 — -0.8; -1.0 percentage of Glycosylated Hemoglobin

Primary: Influence of the Neuroimaging Test on a Finding of Alzheimer's Disease as the Underlying Cause of the Mild Memory Loss — 3; 12; 9; 31 participants

Primary: Change From Baseline to End of 7-day Intervention in Mean Plasma Glucose Derived From 24 Hour Blood Sampling — -13.7; -2.9 mg/dl — p=0.01

Primary: 12-week FACT-Taxane Neurotoxicity Model-adjusted Score in ALC and Placebo Groups — 35.4; 36.3 units on a scale — p=0.17

Primary: Change in BMI z Score — -0.06; -0.09 BMI z score units — p=0.3928

Primary: Amount of Drug Consumed Per Hour in Each Group(Arm) — 16.2; 14.6; 15.3; 16 milliliters per hour

Primary: Response Rate — .125 proportion of participants

Primary: Percentage of Eyes Achieving Uncorrected Visual Acuity (UCVA) of 20/40 or Better at Refractive Stability in Eyes With Best Spectacle-corrected Visual Acuity (BSCVA) of…

Primary: Total Lesion Count — 36.6; 30.7 lesions

Primary: Plasma Levels of Free Fatty Acids, Tumor Necrosis Factor-α, Interleukin-6, and Von Willebrand Factor Antigen

Primary: Toxicity — 0; 1; 2 participants